Bucelon 2 mg Tablet IP
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Bucelon 2 mg Tablet IP is an anti-cancer medicine containing busulfan, an alkylating agent. Its labelling describes it for the treatment of some cancers of the blood, such as chronic myeloid leukemia, and for use in combination as part of haematopoietic progenitor cell transplantation. It is described as working by destroying the DNA and RNA — the genetic material — of cancer cells, which prevents their further growth and multiplication. The doctor decides the dosage and how often it is taken, depending on the patient’s condition.
Product Information
The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of blood cancers such as chronic myeloid leukaemia
- Described for use in combination as part of haematopoietic progenitor cell transplantation
- Also listed for malignant melanoma, Hodgkin’s disease, multiple myeloma, brain tumour, breast cancer, non-small cell lung cancer, ovarian cancer, and lung cancer
- Described as destroying the DNA and RNA of cancer cells to prevent further growth and multiplication
Described Dosage & Administration
- Taken only if advised by the doctor
- The doctor decides the dosage and how often it is taken, depending on the patient’s condition
- Taken exactly as advised by the doctor
Described Side Effects
Commonly described side effects include:
- Decreased blood cells
- Diarrhoea and abdominal pain
- Anxiety
- Fever
- Nausea and vomiting
- Insomnia
- Headache
- Loss of appetite
- Decreased magnesium and potassium levels in the blood
- High glucose levels in the blood
- Stomatitis
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Taken only after consulting the doctor
- The doctor should be informed of any kidney or liver-related problems before use
- Women who are pregnant should consult a doctor before use; described as unsafe for breastfeeding mothers as it may cause toxicity to the baby
- A proper diet should be followed and alcohol avoided during treatment
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains busulfan and is used for blood cancers such as chronic myeloid leukemia and as part of haematopoietic progenitor cell transplantation. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as an alkylating agent that destroys the DNA and RNA of cancer cells, preventing their further growth and multiplication.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.